Efferon raises €4.3m for international expansion of blood-purification devices
Existing private investors backed expansion in Europe, India and Latin America, alongside regulatory and clinical work.
Efferon has raised €4.3 million from existing private investors in the DACH region to expand its hemoadsorption devices into new markets and develop its clinical evidence base.
The company’s devices are designed to remove endotoxins and excessive inflammatory mediators from the bloodstream. Its portfolio includes Efferon LPS and Efferon NEO, used in critical care settings including sepsis and septic shock.
The new investment will support commercial expansion in Europe, India and Latin America, development of a network of 21 distributors, regulatory work and research. Efferon says it will pair its Indian market entry with data collection on how hospitals introduce the technology into clinical workflows.
Efferon reported more than 30,000 treatments and distribution in 46 countries. The company sees the work funded by this investment as preparation for a future full Series A round.
Use of funds
Commercial expansion in Europe, India and Latin America
Distributor development
Regulatory work
Clinical evidence and research